Lobe Sciences (TSE:LOBE) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Lobe Sciences Ltd. is actively pursuing strategies to increase shareholder value, including potential uplisting on major stock exchanges and out-licensing of its proprietary assets, L-130 and Altemia. The company recently secured a $500,000 convertible note to strengthen its financial position ahead of a larger funding round, aimed at better reflecting its scientific achievements in the market valuation. Lobe is also committed to converting short-term debt and preparing for long-term funding strategies, as it believes its psychedelic compound L-130 has unique potential in the market.
For further insights into TSE:LOBE stock, check out TipRanks’ Stock Analysis page.
